

*Journal of Chromatography*, 221 (1980) 393–398

*Biomedical Applications*

Elsevier Scientific Publishing Company, Amsterdam — Printed in The Netherlands

CHROMBIO. 683

## Note

---

### Gas chromatographic determination of maprotiline and its N-desmethyl metabolite in human blood using nitrogen detection

ANTOINE SIOUFI\* and ALAIN RICHARD

*Ciba-Geigy, Centre de Recherche Biopharmaceutique, B.P. 308, 92506 Rueil-Malmaison Cedex (France)*

(First received April 25th, 1980; revised manuscript received July 17th, 1980)

Maprotiline (Ludiomil®) is an antidepressive agent that has been in use for several years. It is found in erythrocytes in concentrations about 2.5 times the plasma concentration [1]. Desmethyl-maprotiline is one of its metabolites.

A double radioisotope derivative (DRID) assay of maprotiline in blood has been described [2] and its clinical applications reported [3]. Electron-capture gas-liquid chromatography (GLC-ECD) using the heptafluorobutyryl derivative of maprotiline was applied to the determination of maprotiline in plasma, blood and urine [4, 5]. Gas chromatography-mass spectrometry (GC-MS) was also used to assay maprotiline from post mortem material [6]. Tricyclic antidepressants and their metabolites were determined in serum by high-performance liquid chromatography (HPLC) [7].

Antipsychotic drugs containing either a secondary or a tertiary amine were determined by gas chromatography using thermionic nitrogen-selective detectors (GLC N-FID) [8–14]. Maprotiline and desmethyl-maprotiline were estimated in serum by GLC N-FID [15]. A comparison between GLC N-FID and DRID for the determination of maprotiline in human plasma was reported [9, 16].

In order to allow the quantitative assay of maprotiline in whole blood by laboratories not equipped with the instrumentation necessary for the DRID method, we describe here a GLC N-FID method for the determination of maprotiline and desmethyl-maprotiline in blood.

## EXPERIMENTAL

### *Chemicals and reagents*

Maprotiline hydrochloride, desmethyl-maprotiline hydrochloride and desipramine hydrochloride were supplied by Ciba-Geigy (Basle, Switzerland). All reagents and solvents are of analytical grade.

The content of four vials of pH 10 Titrisol (Merck 9890; E. Merck, Darmstadt, G.F.R.) is diluted to 500 ml with distilled water to yield the pH 10 buffer used as the extraction buffer.

The solutions of maprotiline hydrochloride, desmethyl-maprotiline hydrochloride and desipramine hydrochloride are prepared in 0.01 *N* sulphuric acid. The aqueous solution of desipramine hydrochloride (internal standard) contains 1 ng/ $\mu$ l.

### *Equipment*

A Hewlett-Packard Model 5710A gas chromatograph equipped with a nitrogen detector (Model 18789A) is used. The column is operated at 245°C, the injector and the detector at 300°C, with a nitrogen flow-rate of 40 ml/min. The flow-rates of hydrogen and air are, respectively, 3 and 30 ml/min. The heating pulse of the cell is 14 V adjusted as recommended by Hewlett-Packard.

The column packing is 3% HI-EFF-8BP on Chromosorb W HP 100–120 mesh (Applied Science Labs., State College, PA, U.S.A.). The packed column (0.30 m  $\times$  3 mm I.D.) is flushed with the carrier gas at a flow-rate of 20 ml/min and heated to 250°C at a rate of 20°C per 15 min. The column temperature is held overnight at 250°C.

### *Extraction and derivatization*

Two hundred microlitres of the internal standard solution are measured into a stoppered glass tube. Then, 1 ml of the sample, 2 ml of pH 10 buffer and 5 ml of heptane containing 3% isoamyl alcohol are added. The tube is shaken mechanically (Infors shaker) for 15 min at 300 rpm and centrifuged at 2000 *g*.

An aliquot volume of the organic phase is transferred to another tube and 2 ml of 0.1 *N* sulphuric acid is added. The tube is shaken mechanically for 15 min at 300 rpm and centrifuged at 2400 *g*. The interface between the two layers must be well defined.

The organic phase is discarded, 1 ml of 0.2 *N* sodium hydroxide, 2 ml of pH 10 buffer and 4 ml of hexane containing 5% ethyl acetate are added. The tube is shaken mechanically for 15 min at 300 rpm and centrifuged at 2000 *g*. A maximum volume of the organic phase is transferred to another tube (care being taken not to withdraw any of the aqueous phase), 50  $\mu$ l of anhydrous pyridine, 20  $\mu$ l of acetic anhydride are added and the stoppered tube is heated at 60°C for 1 h. After cooling to room temperature, 1 ml ethyl acetate and 2 ml of 1 *N* sodium hydroxide are added. The tube is shaken mechanically for 15 min at 300 rpm and centrifuged at 2000 *g*.

A maximum volume of the organic phase is transferred to a conical tube and taken to dryness under a nitrogen stream at 40°C. If the GC run cannot be made until the next day, the organic phase should be stored at -20°C without taking to dryness.

### Gas chromatography

Just before injection onto the column, 50  $\mu$ l of ethyl acetate are added. The tube is shaken on a Vortex mixer and a 2- $\mu$ l portion of the ethyl acetate solution is injected into the gas chromatograph.

The maprotiline (or desmethyl-maprotiline) content is calculated from the peak-area ratio by reference to a calibration curve. This curve is obtained by extraction of blood spiked with increasing amounts of maprotiline (20–400 ng/ml) or increasing amounts of desmethyl-maprotiline (50–400 ng/ml) and a constant amount of internal standard (200 ng/ml).

The calibration curve is stable for 24 h and valid for one week. It must be checked every week to assess its reproducibility.

The authenticity of the chromatographic peaks obtained with the monoacetylated derivatives of maprotiline, desmethyl-maprotiline and desipramine was verified by injecting solutions of the pure synthetic monoacetylated derivatives.

## RESULTS AND DISCUSSION

### Precision and recovery

Tables I and II give the results obtained when the described procedure is applied to blood samples spiked with maprotiline hydrochloride and desmethyl-maprotiline hydrochloride, respectively. Gupta et al. [15] obtained the same results for the estimation of the precision of their method.

TABLE I

PRECISION AND RECOVERY FOR THE DETERMINATION OF MAPROTILINE APPLIED TO SPIKED HUMAN BLOOD SAMPLES

Amount added (ng/ml)	Mean amount found (ng/ml; n = 6)	Precision Reproducibility ( $\pm$ S.D.)	Recovery Accuracy (mean $\pm$ C.V.%)
20	23.3	$\pm$ 1.2	117.0 $\pm$ 5.2
50	47.7	$\pm$ 9.4	95.3 $\pm$ 4.7
100	90.7	$\pm$ 4.0	90.7 $\pm$ 4.4
200	205.0	$\pm$ 8.6	102.7 $\pm$ 4.4
400	392.7	$\pm$ 30.4	98.0 $\pm$ 7.4

TABLE II

PRECISION AND RECOVERY FOR THE DETERMINATION OF DESMETHYL-MAPROTILINE APPLIED TO SPIKED HUMAN BLOOD SAMPLES

Amount added (ng/ml)	Mean amount found (ng/ml; n = 6)	Precision Reproducibility ( $\pm$ S.D.)	Recovery Accuracy (mean $\pm$ C.V.%)
50	51.0	$\pm$ 1.7	103.0 $\pm$ 3.1
100	104.0	$\pm$ 9.6	104.0 $\pm$ 9.6
200	198.5	$\pm$ 6.0	99.0 $\pm$ 3.0
400	363.4	$\pm$ 33.0	91.0 $\pm$ 8.2

### Sensitivity

Concentrations down to 50 ng of maprotiline and desmethyl-maprotiline per ml of blood can be determined accurately. Attempts to use 2 ml of blood instead of 1 ml to improve sensitivity were unsuccessful, because they resulted in a high chemical background.

### Plasma interference and selectivity

Fig. 1 shows that there is no interference from the normal constituents of the blood. Known metabolites of maprotiline, other than desmethyl-maprotiline, are hydroxylated or conjugated compounds [1] and they cannot be extracted or detected by our method. A re-extraction step is involved in the extraction procedure. This step is used to purify the extract, thus avoiding some interfering peaks obtained after derivatization.

GLC N-FID and DRID methods are suitable for maprotiline estimation in patient plasma and their precisions are comparable [9, 16], but DRID is a technique not readily accessible to standard laboratories. GLC-ECD using the heptafluorobutyryl derivative of maprotiline [4, 5] was very sensitive when applied to the pure compound. Its application to biological extracts yields a high chemical background.




Fig. 1. Example of a chromatogram of a 1-ml human blood blank (the arrows indicate the location of the derivatized amines).

Fig. 2. Example of a chromatogram of an actual blood sample containing (see text) 200 ng of desipramine, 70 ng of maprotiline, and 51 ng of desmethyl-maprotiline.

Our results are comparable to those of Gupta et al. [15], but our method offers the advantage of determining maprotiline and desmethyl-maprotiline in whole blood.

Fig. 2 shows the chromatogram of a blood sample withdrawn on the 19th day from a subject who received one 25-mg Ludiomil® tablet twice a day (50 mg of maprotiline hydrochloride per day for a period of 19 days).

#### *Chromatographic conditions*

Silicone stationary phases such as OV-17 (50–50 Me–Ph silicone), SP 2250 DB (50–50 Me–Ph silicone modified for use with basic compounds), OV-25 (25–75 Me–Ph silicone) or SP 2401 DB (trifluoropropyl silicone modified for use with basic compounds) are not suitable for the GLC of acetyl-maprotiline. Acetylated maprotiline and desmethyl-maprotiline either do not separate from each other or are not separated from interference peaks.

More polar stationary phases such as DEGS (diethylene glycol succinate, polyester) or SP 1000 (Carbowax + substituted terephthalic acid) are not suitable for temperatures higher than 220°C.

High-temperature stationary phases such as Poly-S-179 (polyphenyl ether sulfone) and Poly-MPE (polymetaphenoxylene) give peaks with considerable tailing.

The cyclohexanedimethanol succinate (HI-EFF-8BP) has proved very satisfactory for the GLC of acetylated maprotiline and its metabolite; peaks due to extractable impurities elute early, while the desired peaks appear well separated and symmetrical.

#### CONCLUSION

The described GLC N-FID method makes it possible to determine maprotiline and desmethyl-maprotiline quantitatively in whole blood. In laboratories that are not equipped with the instrumentation necessary for the DRID method [2, 3], this method can be used to monitor maprotiline levels during chronic treatment.

#### REFERENCES

- 1 W. Riess, L. Dubey, E.W. Fungfeld, P. Imhof, H. Hürzeler, N. Matussek, T.G. Rajagopalan, F. Raschdorf and K. Schmid, *J. Int. Med. Res.*, 3 (1975) 16.
- 2 W. Riess, *Anal. Chim. Acta*, 68 (1974) 363.
- 3 T.R. Norman, G.D. Burrows, K.P. Maguire and B.A. Scoggins, *Clin. Exp. Pharmacol. Physiol.*, 6 (1979) 211.
- 4 O. Borgå and M. Garle, *J. Chromatogr.*, 68 (1972) 77.
- 5 U.P. Geiger, J.G. Rajagopalan and W. Riess, *J. Chromatogr.*, 114 (1975) 167.
- 6 K. Meinhart, A. Nikiforov and W. Vycudilik, *Arch. Toxicol.*, 33 (1974) 65.
- 7 D.R.A. Uges and P. Bouma, *Pharm. Weekbl. Sci. Ed.*, 1 (1979) 417.
- 8 L.A. Gifford, P. Turner and C.M.B. Pare, *J. Chromatogr.*, 105 (1975) 107.
- 9 D.J. Witts, Depression — The Biochemical and Physiological Role of Ludiomil, *Proc. Int. Symp. Verdala, Malta, 1976, CIBA Laboratories, Horsham, 1977*, p. 169.
- 10 D.J. Witts and P. Turner, *Brit. J. Clin. Pharmacol.*, 4 (1977) 249.
- 11 A.R. Viala, J.P. Cano, A.G. Durand, T. Erlenmaier and R.M. Garreau, *Anal. Chem.*, 49 (1977) 2354.

- 12 H. Dekirmenjian, J.I. Javaid, B. Duslak and J.M. Davis, *J. Chromatogr.*, 160 (1978) 291.
- 13 J.N. Connor, G.F. Johnson and H.M. Solomon, *J. Chromatogr.*, 143 (1977) 415.
- 14 S. Dawling and R.A. Braithwaite, *J. Chromatogr.*, 146 (1978) 449.
- 15 R.N. Gupta, G. Molnar and M.L. Gupta, *Clin. Chem.*, 23 (1977) 1849.
- 16 J.M.E. Wurm, T.R. Norman, K.P. Maguire, G.D. Burrows and B.A. Scoggins, A Comparison of Methods for the Determination of Maprotiline in Human Plasma, Abstract, South East Asian—Western Pacific Regional Meeting of Pharmacologists, 1979.